What types of targets are suitable for solid-phase screening?

Creative Biolabs can screen against purified proteins, peptides, glycoproteins, DNA/RNA, synthetic molecules, or even pathogen components. The key requirement is stability and compatibility with immobilization.

How is the target immobilized, and does it affect activity?

We use several strategies (biotin-streptavidin, covalent coupling, passive adsorption) and validate each method for retention of conformational or functional integrity.

Can I provide my own target, or must Creative Biolabs produce it?

Both are possible. If you supply the target, we'll provide guidelines on purity and quantity. If you prefer, Creative Biolabs can produce and QC it in-house.

How many rounds of screening are typical?

Most campaigns include 2–4 rounds, but we adapt based on enrichment performance. Intermediate analyses help decide whether to proceed or pivot.

Is this platform suitable for antibody or peptide discovery?

Yes. We screen peptide, scFv, Fab, and single-domain antibody libraries. We also offer de novo peptide synthesis or recombinant expression for top hits.

How does this compare to solution-based or cell-based screening?

Solid-phase allows high precision and reproducibility but lacks cellular context. Creative Biolabs can pair this with solution or cell-based platforms for comprehensive validation.

What's the turnaround time?

Most solid-phase screening campaigns take 8–10 weeks, depending on target availability and downstream services.

Can Creative Biolabs help us translate binders into therapeutic or diagnostic candidates?

Absolutely. We offer downstream services like hit validation, target identification, peptide modification, and ligand conjugation for imaging or delivery.

Solid-Phase Strategy based Library Screening Service

Introduction Our Services Workflow Platform Cases Advantages FAQ

Introduction: Binding Precision, Optimized on the Bench

Solid-phase library screening has long served as a cornerstone in molecular selection workflows. By immobilizing target proteins, nucleic acids, or complexes onto a physical surface, researchers can conduct phage display screening with unmatched control over presentation, orientation, and washing conditions. At Creative Biolabs, we offer a next-generation solid-phase platform designed for high-efficiency isolation of peptides, antibodies, and protein domains that bind your targets with high specificity.

What sets Creative Biolabs apart is not just technical expertise—but our attention to the nuanced variables that influence success in immobilized assays. From linker chemistry to microplate optimization, every detail is tailored to your molecule of interest. Whether you're targeting a purified recombinant protein, an epitope of interest, or even a multi-subunit complex, our solid-phase phage display services are designed to minimize off-target noise and maximize your yield of high-value hits.

Application: High-throughput identification of peptide, protein, or antibody binders immobilized on a solid surface.
Problem Solved: Ideal for discovering binding agents that can be used in diagnostic assays, therapeutics, or targeted drug delivery. Ensures stable, reproducible results with reduced false positives.

What We Offer: Smart Screening for Molecular Interactions

Creative Biolabs' screening service is engineered for flexibility, reproducibility, and depth. Clients across therapeutic discovery, diagnostics, and academic research rely on our modular workflow to interrogate libraries against an array of target formats.

Our offerings include:

Screening of phage-displayed peptide, scFv, Fab, or single-domain antibody libraries
Target immobilization via covalent coupling, His-tag/Ni-NTA, or passive adsorption
Optimization of blocking and washing stringency to control for background binding
Multi-round panning with intermediate phage titration and enrichment analysis
Integration with orthogonal techniques (e.g., SPR, ELISA, flow cytometry) for post-screen validation

Creative Biolabs accepts both client-supplied targets and internally produced antigens. Our in-house team can also assist with antigen production, purification, and labeling as part of an integrated package.

How We Work: A Tailored and Transparent Process

At Creative Biolabs, we believe screening should be both strategic and transparent. Our team builds a plan around your project's goals and keeps you updated throughout the campaign. Our typical workflow includes:

Step 1. Project Planning and Target Evaluation

We begin with a detailed consultation to define goals, target characteristics, and appropriate immobilization chemistry.
Step 2. Choose Library

We have a series of high-quality premade libraries for your rapid binder discovery and library construction services to meet your needs.
Step 3. Target Immobilization

Your molecule is attached to the solid phase in a way that preserves conformational integrity and key epitopes.
Step 4. Library Incubation

A phage-displayed library is introduced and allowed to bind under controlled conditions.
Step 5. Washing and Elution

Non-binders are washed away. Specific binders are eluted using customized protocol.
Step 6. Amplification and Re-screening

Eluted phage are amplified and optionally subjected to additional rounds of screening to increase selectivity.
Step 7. Clone Identification and Analysis

DNA from enriched phage is sequenced and analyzed to identify consensus motifs and candidate binders.
Step 8. Optional Functional Validation

Top hits can be synthetically produced or recombinantly expressed for functional assays, affinity testing, or structural modeling.

Deliverables: More Than Just Sequences

Creative Biolabs provides comprehensive documentation and ready-to-use outputs. Standard deliverables include:

Summary report detailing methods, experimental conditions, and enrichment metrics
Sequencing data (Sanger or NGS)
Hit ranking tables and sequence alignment
Optional expression of candidate hits for biochemical testing

Deliverables can be customized to fit publication, diagnostic, or therapeutic development requirements.

Our Platform: Built for Specificity and Consistency

The solid-phase screening platform at Creative Biolabs has been refined to handle diverse targets and varying project demands. Our immobilization methods are compatible with proteins, glycans, nucleic acids, and even synthetic polymers. We use a range of surfaces—from high-binding polystyrene to magnetic beads—to accommodate throughput needs, from small-scale pilot runs to large-scale screens.

We also support hybrid workflows by combining solid-phase panning with:

Solution-phase screening (for validating soluble vs. immobilized preferences)
Cell-based screening (for follow-up validation in cellular contexts)
Ex vivo and in vivo models (when in situ confirmation is needed)

Clients can easily transition from solid-phase to other screening formats with Creative Biolabs' seamless service integration.

Our Expertise in Solid-Phase based Phage Display Screening

Fig.9 Immune Checkpoint Abs. (Creative Biolabs AI)

Immune Checkpoint Antibody Development

Target PD-1, PD-L1, CTLA-4 for immunotherapies.

Fig.10 Tumor Antigen Find. (Creative Biolabs AI)

Tumor Antigen Discovery

Identify antigens for cancer immunotherapy and diagnostics.

Fig.11 Monoclonal Ab Discovery. (Creative Biolabs AI)

Monoclonal Antibody Discovery

Fast-track high-affinity antibodies for disease treatments.

Fig.12 Diagnostic Biomarker Find. (Creative Biolabs AI)

Diagnostic Biomarker Discovery

Isolate biomarkers for early detection of cancers and diseases.

Fig.13 ADC Development. (Creative Biolabs AI)

Antibody-Drug Conjugate (ADC) Development

Isolate antibodies for targeted cancer therapies.

Pathogen Targeting

Develop antibodies and peptides against viral and bacterial pathogens.

Case-Driven Discoveries: The Power of Our Screening Services

Project Goal

Identify functional, high-affinity antibodies targeting the TCR extracellular domain (T1) for immuno-oncology applications.

Strategy

Library Used: Premade Human scFv Antibody Library.
Screening Approach: Positive selection using solid-phase screening and phage ELISA.
Validation Methods: Soluble FACS against Custom engineering T cells.

Key Results

Enrichment Data Positive selection of TCR-specific binders over multiple rounds of screening.	Initial Binder Validation Strong binding signals indicating successful identification of potential binders.
Protein-Level Validation High-affinity binding and confirming specificity.	Cell-Level Validation Selective interaction with TCR-expressing cells, confirming their potential for immune modulation.

Why Choose Creative Biolabs: Expertise Without Compromise

Here's why top research teams and biopharma clients trust Creative Biolabs:

Deep Experience with Complex Targets

From multi-pass membrane proteins to post-translationally modified peptides, we know how to screen what others can't.

Fully Customizable Conditions

No one-size-fits-all protocols—every detail is tuned to your target.

Data Transparency

Receive not only results but also experimental records and interpretation notes at every stage.

Cross-Platform Expertise

Flexibly migrate between solid-phase, solution-phase, or cellular systems within the same project.

Confidentiality and Ethics First

We safeguard your data and IP with rigorous protocols.

Contact Creative Biolabs' team today to discuss your project and discover how we can accelerate your discovery workflow.

FAQs: Everything You Need to Know

Q: What types of targets are suitable for solid-phase screening?
A: Creative Biolabs can screen against purified proteins, peptides, glycoproteins, DNA/RNA, synthetic molecules, or even pathogen components. The key requirement is stability and compatibility with immobilization.
Q: How is the target immobilized, and does it affect activity?
A: We use several strategies (biotin-streptavidin, covalent coupling, passive adsorption) and validate each method for retention of conformational or functional integrity.
Q: Can I provide my own target, or must Creative Biolabs produce it?
A: Both are possible. If you supply the target, we'll provide guidelines on purity and quantity. If you prefer, Creative Biolabs can produce and QC it in-house.
Q: How many rounds of screening are typical?
A: Most campaigns include 2–4 rounds, but we adapt based on enrichment performance. Intermediate analyses help decide whether to proceed or pivot.
Q: Is this platform suitable for antibody or peptide discovery?
A: Yes. We screen peptide, scFv, Fab, and single-domain antibody libraries. We also offer de novo peptide synthesis or recombinant expression for top hits.
Q: How does this compare to solution-based or cell-based screening?
A: Solid-phase allows high precision and reproducibility but lacks cellular context. Creative Biolabs can pair this with solution or cell-based platforms for comprehensive validation.
Q: What's the turnaround time?
A: Most solid-phase screening campaigns take 8–10 weeks, depending on target availability and downstream services.
Q: Can Creative Biolabs help us translate binders into therapeutic or diagnostic candidates?
A: Absolutely. We offer downstream services like hit validation, target identification, peptide modification, and ligand conjugation for imaging or delivery.